Work

Corrigendum to “GLP-1 receptor agonists for weight reduction in people living with obesity but without diabetes: a living benefit-harm modelling study” eClinicalMedicine 2024;73:102661

Year: 2026

Type: erratum

Abstract: After publication, we identified that Wharton et al. (2023) had been erroneously included among the randomised controlled trials (RCTs) informing the semaglutide evidence base (doi.org/10.1002/oby.23673). We sincerely regret this error and have corrected the analyses accordingly. The publication was a secondary analysis of the STEP 5 trial, whose primary report by Garvey et al. (2022) was included in the analysis. This inclusion therefore unintentionally double-counted the same trial population.

Source: EClinicalMedicine

DOI: 10.1016/j.eclinm.2026.104022

Authors: Hannah Moll, Eliane Frey, Philipp Gerber, Bettina Geidl, Marco Kaufmann, Julia Braun, Felix Beuschlein, Milo A. Puhan, Henock G. Yebyo

Institutions: University of Zurich, ETH Zurich, Institute of Pharmaceutical Sciences, University Hospital Zurich, LMU Klinikum, Ludwig-Maximilians-Universität München

Language: English

Topic: Pharmacology and Obesity Treatment

Subfield: Pharmacology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $5,780

OpenAlex ID: W7165797739

Cites:

Cited by:

Related to: